Financial news, markets, and business updates
Roivant's experimental drug, mosliciguat, demonstrates significant efficacy in a mid-stage trial for pulmonary hypertension, signaling potential new treatment avenues.
Key changes to Medicare Advantage plans in Boston are forcing patients, like cancer survivor Eldon Clingan, to seek new providers.
While a drug for Angelman syndrome failed in trials, experts believe other experimental therapies may still hold promise for neurological conditions.
The FDA is revisiting its stance on botanical drugs as hurdles persist for clozapine use and pig kidneys emerge as a potential bridge for transplants.
Bristol Myers Squibb has paused its CAR-T therapy trials for autoimmunity due to severe side effects, raising questions about transparency.
The conflict over measles death counts between CDC leadership and Pennsylvania undermines public health efforts in addressing the outbreak.
Recent findings confirm that recipients of gene-edited pig kidneys can later receive human organ transplants, marking a significant milestone for xenotransplantation.
The trial's deadlock raises significant concerns for mental health professionals, especially in the context of postpartum care.
Novartis celebrates a significant milestone with its BTK inhibitor for multiple sclerosis, advancing the treatment landscape for the disease.
Recent drug pricing agreements expand to additional companies, while Novartis and Bristol Myers suspend cell therapy trials due to safety concerns.
Recent research reveals that Paxlovid, a popular Covid-19 treatment, offers no benefit for long Covid patients compared to placebo.
The House is poised to vote on a funding bill that would block Trump's initiative to control federal research grants, targeting bipartisan support.
MAHA's efforts to reshape American nutrition encounter hurdles stemming from a declining dietitian workforce.
Updated guidelines from leading headache organizations emphasize new migraine treatments while addressing gaps in patient awareness and access.
AstraZeneca's heart disease trial disappoints, showing no added benefit, while a court affirms FDA's handling of drug shortages for prominent diabetes treatments.
AstraZeneca's recent heart disease trial failure underscores the effectiveness of stabilizers over silencers for treating ATTR-CM.
The federal autism advisory committee discusses vaccines as potential autism triggers, sparking controversy amidst calls for more research and transparency.
A year after resigning from the CDC, former staff members highlight ongoing issues and advocate for a reformed public health system free from political bias.
Roivant's new therapy, Lisraya, recently approved by the FDA, offers a non-steroidal option for treating dermatomyositis.
Health Secretary Robert F. Kennedy Jr. faces backlash over vaccine misinformation as PA confirms measles-related deaths; tensions escalate with state officials.